ClinicalTrials.gg
RecruitingNCT07120087MyPREVUpdated Jul 23, 2026

Evaluation of an Online Intervention to Educate Women at High Risk of Breast Cancer on How to Help Reduce Their Risk.

An interventional study of Intervention in Breast Cancer, sponsored by UNICANCER. Recruiting at 3 sites in 2 countries. Open to female participants aged 40 Years to 74 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-23.

Sponsored by UNICANCER · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,508
Allocation
Not applicable
Ages
40 Years to 74 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies in Breast Neoplasms by UNICANCER — 15 open to participants now, 27 under way, 7 of them phase 3. Breast Neoplasms · UNICANCER.

Planned enrollment
9th of 59
1,508 · median 170
Started
2026
with 5 others
No phase
14 of 64
2 open now
Primary completion
2026-12
later than 10 of 26 live
Registered
58th of 64
by date

Among the 64 studies in Breast Neoplasms by UNICANCER, this one is the 9th largest by planned enrollment of the 59 interventional ones that give a count, is one of 6 that started in 2026, is one of 14 with no phase, reaches primary completion later than 10 of the 26 other live ones, and was the 58th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

15 of the 64 studies in Breast Neoplasms by UNICANCER are open now, in 9 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 40 Years to 74 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Breast Neoplasms by UNICANCER, or all of them as a file.
02

Study summary

Breast cancer remains the most common cancer among women and a major cause of death despite advances in screening and treatment. Current screening programs are not personalized and are experiencing declining participation. A promising strategy for breast cancer control would be to implement risk-based prevention and early screening, targeting individuals at high risk of developing breast cancer, in order to improve chances of cure and reduce the need for more intensive treatments. The MyPeBS study was designed to assess whether personalized breast cancer screening (based on an individual's risk of developing breast cancer) is as effective as, or more effective than, current standard screening.

Lifestyle interventions involving changes in diet or physical activity, for example, have been shown to be effective in reducing the risk of developing breast cancer, whether low or high. The MyPeBS study evaluates personalized screening but offers limited information on breast cancer prevention. MyPREV is a project that aims to assess the feasibility and impact of a personalized online program on breast cancer risk reduction measures. This program is offered to women at high risk of developing breast cancer as part of the European MyPeBS screening study.

The main objective is to evaluate adherence to a personalized, online breast cancer prevention program focused on lifestyle and its acceptance among women at high or very high risk of developing cancer who participated in the MyPeBS study.

Read the detailed description

MyPREV is a prospective interventional cohort study. The study is based on an online educational, medical, and motivational intervention (webinar and online personalized clinical visit) dedicated to promoting and implementing lifestyle-based breast cancer risk-reduction measures among women identified in the MyPeBS trial as being at high or very high risk of breast cancer based on Polygenic risk score (PRS) and clinical scores. In MyPeBS, 34.4% of the women in the risk-based arm were estimated to be at high (33.03%) or very high (1.37%) to develop a breast cancer within 5 years.

The study MyPREV plans to invite 3016 women (1821 in France and 1195 in Italy for the sites CPO and ISPRO). The expected participation rate is 50%, so around 1507 women (910 in France and 597 in Italy for the sites CPO and ISPRO). The intervention consist of a virtual webinar and an online personalized clinical visit where the personalized prevention plan will be created.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Prevent and treat - breast cancer screening
04

Who can participate

Ages eligible
40 Years to 74 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female (whether born female or not)
  2. Women aged 40 to 74 years (inclusive)
  3. Women who have participated in, or are participating in the MyPeBS study and who fulfilled all the inclusion and non-inclusion criteria for the MyPeBS study.
  4. Women able to express their non-opposition to participate in the intervention
  5. Women who were assessed as being at high (≥≥1.67% - 5.9%) or very high (≥≥6%) risk of invasive breast cancer at 5 years in the MyPeBS study

Exclusion criteria

Exclusion Criteria:

1. Women who developed a breast cancer during their follow-up in the MyPeBS study

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,508 participants (estimated)

Study arms

  • Other
    intervention

    intervention

    Behavioral: Intervention

Interventions

  • BehavioralIntervention

    Virual Webinar and online personalised clinical visit

06

What researchers measure

Primary outcomes

  1. Acceptance

    To assess the acceptance of a full, targeted, online, educational and motivational intervention on breast cancer risk reduction measures among women who took part in MyPeBS and were identified to have a high or very high risk of breast cancer.

    Time frame: From start of the inclusion up to the end of inclusions

Secondary outcomes

  1. Prevalence of risk reduction targets

    Assess the prevalence of breast cancer risk reduction targets (potentially modifiable factors) among women willing to participate

    Time frame: From start of the inclusion up to the end of inclusions

  2. WCRF

    Assess the participants' progress in modifying some of their behaviours according to the WCRF score at 3 months and 1 year

    Time frame: At 3 months, 1 year

  3. Strate-Trait Anxiety Inventory - State (STAI-S)

    Evaluate patient characteristics (age, country, education level, professional occupation, Strate-Trait Anxiety Inventory \[STAI\] score at baseline in MyPeBS, level of breast cancer risk) associated with participation or non-participation in the proposed program and receipt of the proposed intervention

    Time frame: At baseline

  4. Subject knowledge and perception of knowledge

    Evaluate the knowledge and perception of knowledge regarding breast cancer risk and risk reduction measures with a specific questionnaire

    Time frame: At baseline, 1 year

  5. Subject anxiety

    Subject anxiety will be evaluated using the State-Trait Anxiety Inventory (STAI) questionaire

    Time frame: At baseline, 1 year

  6. Subject satisfaction

    Subject satisfaction will be measured using a specific questionnaire.

    Time frame: At baseline, 1 year

  7. Levers and barriers for lifestyle modifications

    Evaluate the prevalence of predefined or self-assessed potential levers and barriers for lifestyle modifications

    Time frame: At 1 year

07

Study locations

1 of 3 sites recruiting
  • Centre Médical et Dentaire de Lyon MGEN
    Lyon, 69003, France
    Recruiting
  • Gustave Roussy
    Villejuif, France
    Not yet recruiting
  • AOU Città della Salute e della Scienza - CPO PiedmontSSD Epidemiologia e Screening
    Torino, Italy
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Unicancer will share de-identified individual data that underlie the results reported. A decision concerning the sharing of other study documents, including protocol and statistical analysis plan will be examined upon request.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Unicancer will consider access to study data upon written detailed request sent to Unicancer, from 6 months until 5 years after publication of summary data.

Access criteria: The data shared will be limit to that required for independent mandated verification of the published results, the applicant will need authorization from Unicancer for personal access, and data will only be transferred after signing of a data access agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Dec 2026, 10 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 10 months is below that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2025
First posted
Aug 13, 2025
StartActual
Feb 19, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jun 2027
Last update
Jul 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07120087
Lead sponsor
UNICANCER
Collaborators
European Union
Responsible party
Sponsor
First posted
Aug 13, 2025
Start date
Feb 19, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Jun 2027 (estimated)
Last update
Jul 23, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion